Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine. Nilvadipine, licensed to treat hypertension, reduces amyloid production, increases regional cerebral blood flow, and has demonstrated anti-inflammatory and anti-tau activity in preclinical studies, properties that could have disease-modifying effects for Alzheimer disease. We aimed to determine if nilvadipine was effective in slowing cognitive decline in subjects with mild to moderate Alzheimer disease. METHODS AND FINDINGS: NILVAD was an 18-month, randomised, placebo-controlled, double-blind trial that randomised participants between 15 May 2013 and 13 April 2015. The study was conducted at 23 academic centres in nine European countries. Of 577 participants screened, 511 were eligible and were randomised (258 to placebo, 253 to nilvadipine). Participants took a trial treatment capsule once a day after breakfast for 78 weeks. Participants were aged >50 years, meeting National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's disease Criteria (NINCDS-ADRDA) for diagnosis of probable Alzheimer disease, with a Standardised Mini-Mental State Examination (SMMSE) score of ≥12 and <27. Participants were randomly assigned to 8 mg sustained-release nilvadipine or matched placebo. The a priori defined primary outcome was progression on the Alzheimer's Disease Assessment Scale Cognitive Subscale-12 (ADAS-Cog 12) in the modified intention-to-treat (mITT) population (n = 498), with the Clinical Dementia Rating Scale sum of boxes (CDR-sb) as a gated co-primary outcome, eligible to be promoted to primary end point conditional on a significant effect on the ADAS-Cog 12. The analysis set had a mean age of 73 years and was 62% female. Baseline demographic and Alzheimer disease-specific characteristics were similar between treatment groups, with reported mean of 1.7 years since diagnosis and mean SMMSE of 20.4. The prespecified primary analyses failed to show any treatment benefit for nilvadipine on the co-primary outcome (p = 0.465). Decline from baseline in ADAS-Cog 12 on placebo was 0.79 (95% CI, -0.07-1.64) at 13 weeks, 6.41 (5.33-7.49) at 52 weeks, and 9.63 (8.33-10.93) at 78 weeks and on nilvadipine was 0.88 (0.02-1.74) at 13 weeks, 5.75 (4.66-6.85) at 52 weeks, and 9.41 (8.09-10.73) at 78 weeks. Exploratory analyses of the planned secondary outcomes showed no substantial effects, including on the CDR-sb or the Disability Assessment for Dementia. Nilvadipine appeared to be safe and well tolerated. Mortality was similar between groups (3 on nilvadipine, 4 on placebo); higher counts of adverse events (AEs) on nilvadipine (1,129 versus 1,030), and serious adverse events (SAEs; 146 versus 101), were observed. There were 14 withdrawals because of AEs. Major limitations of this study were that subjects had established dementia and the likelihood that non-Alzheimer subjects were included because of the lack of biomarker confirmation of the presence of brain amyloid. CONCLUSIONS: The results do not suggest benefit of nilvadipine as a treatment in a population spanning mild to moderate Alzheimer disease. TRIAL REGISTRATION: Clinicaltrials.gov NCT02017340, EudraCT number 2012-002764-27.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A phase III trial (NCT02017340) testing the efficacy and safety of nilvadipine (29) in participants with mild to moderate AD indicated that, while the drug demonstrated good safety, it did not show significant benefits in slowing cognitive decline in AD patients.477”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [477]
The cited source says what the claim attributes to it.
In the citing paper
“The dihydropyridine calcium channel blocker nilvadipine with a capacity of lowering Aβ production and increasing clearance Aβ was evaluated for neuroprotective and anti-inflammatory properties (Lawlor et al., 2018).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Lawlor et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Forette, F., Seux, M.-L., Staessen, J. A., Thijs, L., Birkenhäger, W. H., Babarskiene, M.-R., Babeanu, S., Bossini, A., Gil-Extremera, B., Girerd, X., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03086-4 · Cited by 1,441 · cited 1×
“In the treatment of Systolic Hypertension in Europe (Syst-Eur) trial, which involved over 2,400 older participants with systolic hypertension treated with the DHP calcium channel blocker, nitrendipine, there was a reported 55% reduction in the incidence of Alzheimer disease [12,13].”
The Clinical Diagnosis of Alzheimer's Disease
Wade, J. P. H., Mirsen, T. R., Hachinski, V. C., Fisman, M., Lau, C., & Merskey, H. (1987) · Archives of Neurology · doi:10.1001/archneur.1987.00520130016010 · Cited by 1,374
Forette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898 · cited 1×
“In the treatment of Systolic Hypertension in Europe (Syst-Eur) trial, which involved over 2,400 older participants with systolic hypertension treated with the DHP calcium channel blocker, nitrendipine, there was a reported 55% reduction in the incidence of Alzheimer disease [12,13].”
Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Cited by
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
“Three 5HT6 antagonists and the calcium channel blocker nilvadipine 203,204 have also been ineffective.”
Self-citationRetractedAlzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Clinical trials of new drugs for Alzheimer disease
Huang, L.-K., Chao, S.-P., & Hu, C.-J. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0609-7 · Cited by 702
Economic burden of Alzheimer disease and managed care considerations
(2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2020.88482 · Cited by 398
SYK coordinates neuroprotective microglial responses in neurodegenerative disease
Ennerfelt, H., Frost, E. L., Shapiro, D. A., Holliday, C., Zengeler, K. E., Voithofer, G., Bolte, A. C., Lammert, C. R., Kulas, J. A., Ulland, T. K., et al. (2022) · Cell · doi:10.1016/j.cell.2022.09.030 · Cited by 297
“Though the ability of SYK to modulate Aβ and tau biology has been explored in previous in vitro studies using immortalized CNS lines and pharmacological agents with well-described off-target effects (Lawlor et al., 2018; Paris et al., 2014), the extent to which SYK influences in vivo microglial responses and neurodege…”
Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease
Athar, T., Al Balushi, K., & Khan, S. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06512-9 · Cited by 247
Alzheimer’s Disease: Key Insights from Two Decades of Clinical Trial Failures
Kim, C. K., Lee, Y. R., Ong, L., Gold, M., Kalali, A., & Sarkar, J. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215699 · Cited by 241
Drug repositioning and repurposing for Alzheimer disease
Ballard, C., Aarsland, D., Cummings, J., O’Brien, J., Mills, R., Molinuevo, J. L., Fladby, T., Williams, G., Doherty, P., Corbett, A., et al. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0397-4 · Cited by 201
Plascencia-Villa, G., & Perry, G. (2021) · Antioxidants & Redox Signaling · doi:10.1089/ars.2020.8134 · Cited by 188
“Here, 511 subjects received 8 mg/day for 78 weeks, indicating that the compound was safe and well tolerated, but unfortunately without benefits in cognitive decline (99).”
BackgroundShaw, K., Bell, L., Boyd, K., Grijseels, D. M., Clarke, D., Bonnar, O., Crombag, H. S., & Hall, C. N. (2021) · Nature Communications · doi:10.1038/s41467-021-23508-y · Cited by 184
Albertini, C., Salerno, A., de Sena Murteira Pinheiro, P., & Bolognesi, M. L. (2021) · Medicinal Research Reviews · doi:10.1002/med.21699 · Cited by 179
“Conversely, 1,4‐dihydropyridine (1,4‐DHP) is the core fragment of well‐known calcium channel antagonists (Figure 13B), which have reached phase III AD clinical trial.(123) Indeed, increased”
BackgroundAlbasri, A., Hattle, M., Koshiaris, C., Dunnigan, A., Paxton, B., Fox, S. E., Smith, M., Archer, L., Levis, B., Payne, R. A., et al. (2021) · BMJ · doi:10.1136/bmj.n189 · Cited by 163
Ferretti, M. T., Martinkova, J., Biskup, E., Benke, T., Gialdini, G., Nedelska, Z., Rauen, K., Mantua, V., Religa, D., Hort, J., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14174 · Cited by 147
Cortical graph neural network for AD and MCI diagnosis and transfer learning across populations
Wee, C.-Y., Liu, C., Lee, A., Poh, J. S., Ji, H., & Qiu, A. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.101929 · Cited by 144
Boada, M., López, O. L., Olazarán, J., Núñez, L., Pfeffer, M., Paricio, M., Lorites, J., Piñol‐Ripoll, G., Gámez, J. E., Anaya, F., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12137 · Cited by 143
Self-citationAn update on the novel and approved drugs for Alzheimer disease
Alhazmi, H. A., & Albratty, M. (2022) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2022.10.004 · Cited by 122
“The dihydropyridine calcium channel blocker nilvadipine with a capacity of lowering Ab production and increasing clearance Ab was evaluated for neuroprotective and anti-inflammatory properties (Lawlor et al., 2018).”
Calcium-Handling Defects and Neurodegenerative Disease
Schrank, S., Barrington, N. M., & Stutzmann, G. E. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a035212 · Cited by 122
Dhapola, R., Sarma, P., Medhi, B., Prakash, A., & HariKrishnaReddy, D. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02612-6 · Cited by 123
“The recruitment status of the study is completed [88].”
BackgroundMitochondrial Calcium Deregulation in the Mechanism of Beta-Amyloid and Tau Pathology
Esteras, N., & Abramov, A. Y. (2020) · Cells · doi:10.3390/cells9092135 · Cited by 103
Inflammatory Cascade in Alzheimer’s Disease Pathogenesis: A Review of Experimental Findings
de Oliveira, J., Kucharska, E., Garcez, M. L., Rodrigues, M. S., Quevedo, J., Moreno-Gonzalez, I., & Budni, J. (2021) · Cells · doi:10.3390/cells10102581 · Cited by 102
“For instance, Nivaldipine that showed potential anti-inflammatory effects in animals, was not beneficial in treating mild to moderate AD [227].”
Advances in Alzheimer’s disease’s pharmacological treatment
Filho, C. E. C., Loss, L. B., Pereira, C. M., Rossoni, J. V., Barcelos, R. M., Chiarelli-Neto, O., da Silva, B. S., Ambrósio, R. P., Castro, F. C. D. A. Q., Teixeira, S. F., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1101452 · Cited by 123
“However, clinical trial results do not suggest benefit of nilvadipine as a treatment to AD (Lawlor et al., 2018; Abdullah et al., 2020).”
BackgroundWang, X., & Zheng, W. (2019) · The FASEB Journal · doi:10.1096/fj.201801751r · Cited by 98
Walker, V. M., Kehoe, P. G., Martin, R. M., & Davies, N. M. (2020) · International Journal of Epidemiology · doi:10.1093/ije/dyz155 · Cited by 96
Walker, V. M., Kehoe, P. G., Martin, R. M., & Davies, N. M. (2018) · doi:10.1101/486878 · Cited by 96
Blood Pressure Variability and Progression of Clinical Alzheimer Disease
de Heus, R. A. A., Olde Rikkert, M. G. M., Tully, P. J., Lawlor, B. A., Claassen, J. A. H. R., & for the NILVAD Study Group (2019) · Hypertension · doi:10.1161/hypertensionaha.119.13664 · Cited by 88
Self-citationKorte, N., Barkaway, A., Wells, J. A., Freitas, F., Sethi, H., Andrews, S. P., Skidmore, J., Stevens, B., & Attwell, D. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01753-w · Cited by 110
“However, in a phase 3 clinical trial, a nimodipine-related drug, nilvadipine, which also increases CBF, did not reduce cognitive decline in human patients with mild to moderate AD 78 , perhaps because the drug was started only 4.3 years after symptom onset.”
BackgroundInfluentialThe Song Remains the Same: International Relations After COVID-19
Drezner, D. W. (2020) · International Organization · doi:10.1017/s0020818320000351 · Cited by 94
Türkeş, C., Demir, Y., & Beydemir, Ş. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1736631 · Cited by 84
Türkeş, C., Demir, Y., & Beydemir, Ş. (2019) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-019-03009-x · Cited by 83
Studying Public Perception about Vaccination: A Sentiment Analysis of Tweets
Raghupathi, V., Ren, J., & Raghupathi, W. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17103464 · Cited by 93
Deep learning applications in pulmonary medical imaging: recent updates and insights on COVID-19
Farhat, H. J., Sakr, G. E., & Kilany, R. (2020) · Machine Vision and Applications · doi:10.1007/s00138-020-01101-5 · Cited by 93
Sex difference in human diseases: mechanistic insights and clinical implications
Shi, Y., Ma, J., Li, S., Liu, C., Liu, Y., Chen, J., Liu, N., Liu, S., & Huang, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01929-7 · Cited by 95
“494 Furthermore, women who took high-dose statins had a decreased risk of developing Alzheimer ’ s disease., but not in black men.”
BackgroundRepurposed agents in the Alzheimer’s disease drug development pipeline
Bauzon, J., Lee, G., & Cummings, J. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00662-x · Cited by 77
Effects of Nilvadipine on Cerebral Blood Flow in Patients With Alzheimer Disease: A Randomized Trial
de Jong, D. L. K., de Heus, R. A. A., Rijpma, A., Donders, R. A. R. T., Rikkert, M. G. M. O., Günther, M., LAWLOR, B. A., van Osch, M. J. P., & Claassen, J. A. H. R. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.12892 · Cited by 80
Self-citationNicoletti, A. S. Q., Baschi, R., Cicero, C. E., Iacono, S., Re, V. L., Luca, A., Schirò, G., & Monastero, R. (2023) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111821 · Cited by 89
Ca2+ Dyshomeostasis Disrupts Neuronal and Synaptic Function in Alzheimer’s Disease
McDaid, J., Mustaly-Kalimi, S., & Stutzmann, G. E. (2020) · Cells · doi:10.3390/cells9122655 · Cited by 73
“In addition, the clinically used L-type VGCC inhibitor isradipine has been shown to be neuroprotective in an AD mouse model [22], as has the beta-blocker carvedilol [47], however results from a recent large clinical study suggested no benefit of the VGCC antagonist nilvadipine as a treatment for AD [118].”
ResultEndoplasmic reticulum stress in Alzheimer's disease: Molecular mechanisms and therapeutic prospects
Nagar, P., Sharma, P., Dhapola, R., Kumari, S., Medhi, B., & HariKrishnaReddy, D. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121983 · Cited by 76
Current and evolving treatment strategies for the Alzheimer disease continuum
(2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2020.88481 · Cited by 66
A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease
Maciejewska, K., Czarnecka, K., & Szymański, P. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00293-5 · Cited by 64
Astroglial activation: Current concepts and future directions
Edison, P. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13678 · Cited by 61
“120 Tau aggregatesincreasecytosoliccalciumandROSgenerationviaNADPH.”
Can We Treat Neuroinflammation in Alzheimer’s Disease?
Sánchez‐Sarasúa, S., Fernández-Pérez, I., Espinosa‐Fernández, V., Sánchez‐Pérez, A. M., & Ledesma, J. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228751 · Cited by 67
“Nilvadipine (8 mg/day) Pyridine (crude coal tar) 511 (>50) 18 months NT = ADAS-Cog 12 = CDR-sb = DAD [62] 2018”
BackgroundAutomatic classification of canine thoracic radiographs using deep learning
Banzato, T., Wodziński, M., Burti, S., Osti, V. L., Rossoni, V., Atzori, M., & Zotti, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-83515-3 · Cited by 87
Therapeutic Strategies to Target Calcium Dysregulation in Alzheimer’s Disease
Calvo-Rodríguez, M., Kharitonova, E. K., & Bacskai, B. J. (2020) · Cells · doi:10.3390/cells9112513 · Cited by 68
“In addition, AD patients taking L-type VGCCs inhibitors such as nilvadipine (NILVAD multicenter trial) showed reduced Aβ levels but no improvement in cognitive decline [34,35].”
BackgroundThe molecular mechanism, targets, and novel molecules in the treatment of Alzheimer’s disease
Verma, A., Waiker, D. K., Bhardwaj, B., Saraf, P., & Shrivastava, S. K. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105562 · Cited by 60
Martínková, J., Quevenco, F., Karcher, H., Ferrari, A., Sandset, E. C., Szoeke, C. E. I., Hort, J., Schmidt, R., Chadha, A. S., & Ferretti, M. T. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.24124 · Cited by 68
Antihypertensive agents in Alzheimer’s disease: beyond vascular protection
Lebouvier, T., Chen, Y., Duriez, P., Pasquier, F., & Bordet, R. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1708195 · Cited by 55
“One interesting pharmacogenetics study showed that the use of ACE-inhibitors during 1 year might slow the cognitive decline in patients with AD, but only for APOE4 carriers of specific ACE genotypes [47].”
BackgroundResultInfluentialSelf-citationfor the NILVAD Study Group, Dyer, A. H., LAWLOR, B. A., & Kennelly, S. (2020) · BMC Geriatrics · doi:10.1186/s12877-020-01531-w · Cited by 59
Self-citationFurazans in Medicinal Chemistry
Mancini, R. S., Barden, C., Weaver, D. F., & Reed, M. A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01901 · Cited by 60
Hopp, S. C. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24585 · Cited by 52
“Despite promising preclinical data in animal models of PD (Guzman et al., 2018; Ilijic et al., 2011) and AD (Paris et al., 2011), Phase III trials of isradipine and nilvadipine recently failed to improve or slow progression of PD (Simuni, 2019) and AD (Lawlor et al., 2018), respectively.”
BackgroundMechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer’s Disease
Padhi, D., & Govindaraju, T. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00335 · Cited by 47
Guan, P.-P., Cao, L., Yang, Y., & Wang, P. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.757515 · Cited by 53
Unveiling the impact of aging on BBB and Alzheimer's disease: Factors and therapeutic implications
Nelson, V. K., Jha, N. K., Nuli, M. V., Gupta, S. K., Kanna, S., Gahtani, R. M., Hani, U., Singh, A. K., Abomughaid, M. M., Abomughayedh, A. M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102224 · Cited by 48
Dyer, A. H., Murphy, C., LAWLOR, B. A., Kennelly, S., & for the NILVAD Study Group (2020) · Aging & Mental Health · doi:10.1080/13607863.2020.1745146 · Cited by 49
“In the NILVAD cohort, participants experienced clinically meaningful progression in both cognitive impairment and dementia severity in line with previous results (Lawlor et al., 2014, 2018).”
ResultSelf-citationDyer, A. H., Murphy, C., Lawlor, B., Kennelly, S. P., Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., et al. (2020) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2019.08.006 · Cited by 39
Self-citationEvolving therapeutic interventions for the management and treatment of Alzheimer’s disease
Ahmad, F., Karan, A., Sharma, R., Sharma, N. S., Sundar, V., Jayaraj, R. L., Mukherjee, S., & DeCoster, M. A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102229 · Cited by 43
Wang, Q., Liu, Q., Luo, G., Liu, Z., Huang, J., Zhou, Y., Zhou, Y., Xu, W., & Cheng, J. (2020) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-020-01325-5 · Cited by 46
Current druggable targets for therapeutic control of Alzheimer's disease
Gupta, G. L., & Samant, N. P. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106549 · Cited by 41
You, T.-Y., Dong, Q., & Cui, M. (2022) · Aging and Disease · doi:10.14336/ad.2022.1204 · Cited by 44
“Nilvedipine has benefited a subgroup of moderate AD patients by improving hippocampal blood flow [126],”
BackgroundGiménez, V., & Nunes, B. (2019) · Environmental Science and Pollution Research · doi:10.1007/s11356-019-04653-w · Cited by 36
Ouk, M., Wu, C., Rabin, J. S., Edwards, J. D., Ramirez, J., Masellis, M., Swartz, R. H., Herrmann, N., Lanctôt, K. L., Black, S. E., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.12.011 · Cited by 35
“…their antihypertensive mechanisms of action, and in their effects on pathways unrelated to blood pressure control, it has been hypothesized that different classes of antihypertensives may vary in their effects on neurodegeneration and cognitive decline (Edwards et al., 2017; Lawlor et al., 2018).”
Centering Sex Workers’ Voices in Law and Social Policy
Benoit, C., Unsworth, R., Healey, P., Smith, M., & Jansson, M. (2021) · Sexuality Research and Social Policy · doi:10.1007/s13178-021-00576-9 · Cited by 32
The role of L-type calcium channels in neuronal excitability and aging
Moore, S. J., & Murphy, G. G. (2020) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2020.107230 · Cited by 35
Ou, Y., Yang, Y., Shen, X., Ma, Y., Chen, S.-D., Dong, Q., Tan, L., & Yu, J. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00782-y · Cited by 35
Ghimire, A., Rehman, S. A., Subhani, A., Khan, M. A., Rahman, Z., Iqubal, M. K., & Iqubal, A. (2025) · hLife · doi:10.1016/j.hlife.2024.11.006 · Cited by 38
“These drugs, owing to their anti-in fl ammatory properties, are being tested in different phases of clinical trials (NCT02017340, NCT01931566, NCT02284906) [140,141].”
Comparison of Antihypertensive Drug Classes for Dementia Prevention
Walker, V. M., Davies, N. M., Martin, R. M., & Kehoe, P. G. (2020) · Epidemiology · doi:10.1097/ede.0000000000001245 · Cited by 33
Jain, S., Singh, R., Paliwal, S., & Sharma, S. K. (2023) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557523666230511122435 · Cited by 39
Impact and Trends in Global Ophthalmology
Williams, L. B., Prakalapakorn, S. G., Ansari, Z., & Goldhardt, R. (2020) · Current Ophthalmology Reports · doi:10.1007/s40135-020-00245-x · Cited by 38
Neuro-regeneration Therapeutic for Alzheimer’s Dementia: Perspectives on Neurotrophic Activity
Sun, M., & Alkon, D. L. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.07.008 · Cited by 31
Alzheimer’s Disease Etiology Hypotheses and Therapeutic Strategies: A Perspective
Scarano, N., Musumeci, F., Casini, B., Brullo, C., D’Ursi, P., Fossa, P., Schenone, S., & Cichero, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146980 · Cited by 38
“Its phase III clinical evaluation highlighted a good safety profile, but a lack of efficacy in slowing down cognitive impairment [154].”
Alzheimer’s Disease Research Using Human Microglia
Lue, L., Beach, T. G., & Walker, D. G. (2019) · Cells · doi:10.3390/cells8080838 · Cited by 32
Advances in the discovery of heterocyclic-based drugs against Alzheimer’s disease
Sánchez, J. D., Alcántara, A. R., González, J. F., & Sánchez-Montero, J. M. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2264766 · Cited by 26
Abdullah, L. I., Crawford, F., Tsolaki, M., Börjesson‐Hanson, A., Rikkert, M. G. M. O., Pasquier, F., Wallin, A., Kennelly, S., Ait‐Ghezala, G., Paris, D., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00149 · Cited by 26
Self-citationSingle and Cross-Disorder Detection for Autism and Schizophrenia
Wawer, A., Chojnicka, I., Okruszek, Ł., & Sarzyńska‐Wawer, J. (2021) · Cognitive Computation · doi:10.1007/s12559-021-09834-9 · Cited by 27
Combined drug triads for synergic neuroprotection in retinal degeneration
Maneu, V., Lax, P., de Diego, A. M. G., Cuenca, N., & de Diego, A. M. G. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112911 · Cited by 23
Mumtaz, I., Ayaz, M. O., Khan, M. S., Manzoor, U., Ganayee, M. A., Bhat, A. Q., Dar, G. H., Alghamdi, B. S. A., Hashem, A. M., Dar, M. J., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.977411 · Cited by 24
Lithium Provides Broad Therapeutic Benefits in an Alzheimer’s Disease Mouse Model
Wiseman, A. L., Briggs, C. A., Peritt, A., Kapecki, N., Peterson, D. A., Shim, S. S., & Stutzmann, G. E. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220758 · Cited by 23
Dyer, A. H., Murphy, C., Segurado, R., LAWLOR, B. A., Kennelly, S., & for the NILVAD Study Group (2019) · The Journals of Gerontology Series A · doi:10.1093/gerona/glz244 · Cited by 30
Self-citationMorin, A., Mouzon, B., Ferguson, S., Paris, D., Browning, M., Stewart, W. B., Jr., Mullan, M., & Crawford, F. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01045-x · Cited by 22
Self-citationChaudhary, B. N., Kumari, S., Dhapola, R., Sharma, P., Paidlewar, M., Vellingiri, B., Medhi, B., & HariKrishnaReddy, D. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117211 · Cited by 33
Murphy, C., Dyer, A. H., LAWLOR, B. A., Kennelly, S., & NILVAD Study Group (2020) · Age and Ageing · doi:10.1093/ageing/afaa067 · Cited by 23
Self-citationAquino, C. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.694329 · Cited by 24
“Nilvadipine (37) Dihydropyridine (DHP) calcium”
de Heus, R. A. A., de Jong, D. L. K., Rijpma, A., LAWLOR, B. A., Rikkert, M. G. M. O., & Claassen, J. A. H. R. (2020) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaa129 · Cited by 23
Self-citationIntegrating planetary health into healthcare: A document analysis
Kalogirou, M. R., Dahlke, S., Davidson, S., & Yamamoto, S. S. (2021) · Health Policy · doi:10.1016/j.healthpol.2021.04.002 · Cited by 22
Repurposing Antihypertensive Drugs for the Management of Alzheimer’s Disease
Law, C. S. W., & Yeong, K. Y. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200312114223 · Cited by 18
Kuang, Z.-M. (2020) · Cardiology Research and Practice · doi:10.1155/2020/1484357 · Cited by 22
“However, an article published in PLoS Medicine in 2018 did not show any benefit from antihypertensive therapy in patients with mild-to-moderate AD [25].”
BackgroundYang, H., Cheng, Z., Li, Z., Jiang, Y., Zhao, J., Wu, Y., Gu, S., & Xu, H. (2019) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5179 · Cited by 17
“),(18,20) as well as to assess the severity of AD(22,23) and the efficacy of antidementia treatment.(24,25) In addition, ADAS‐Cog can also be used to discriminate AD from depression(19) and vascular dementia.”
Hypertension and Mild Cognitive Impairment: State-of-the-Art Review
Shajahan, S., Peters, R., Carcel, C., Woodward, M., Harris, K., & Anderson, C. S. (2024) · American Journal of Hypertension · doi:10.1093/ajh/hpae007 · Cited by 20
Das, V., Miller, J. H., Goud, A. C., Annadurai, N., Sanctis, J. B. D., Hrubá, L., & Hajdúch, M. (2024) · Medicinal Research Reviews · doi:10.1002/med.22033 · Cited by 16
de Heus, R. A. A., Donders, R., Santoso, A. M. M., Rikkert, M. G. M. O., LAWLOR, B. A., Claassen, J. A. H. R., for the Nilvad Study Group, Segurado, R., Howard, R. J., Pasquier, F., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.011938 · Cited by 19
“A complete description of the trial has been published previously.19 The main outcome of the trial and any changes made to the study protocol after trial commencement have been reported by Lawlor et al (2018).20”
MethodInfluentialSelf-citationChen, Y. S., Lebouvier, T., Skrobala, E., Volpe‐Gillot, L., Huvent‐Grelle, D., Jourdan, N., Leroy, M., Richard, F., Pasquier, F., & and the Meotis network (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12048 · Cited by 14
Self-citationParvalbumin as a sex-specific target in Alzheimer’s disease research – A mini-review
Terstege, D. J., & Epp, J. R. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105370 · Cited by 14
Murphy, C., Dyer, A. H., LAWLOR, B. A., Kennelly, S., & for the NILVAD study group (2023) · PLoS ONE · doi:10.1371/journal.pone.0285529 · Cited by 17
Self-citationLou, I. X., Chen, J., Ali, K., Shaikh, A. L., & Chen, Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190604 · Cited by 17
“(2018) indicate that nilvadipine did not produce significant changes in cognitive decline in patients with mild to moderate AD after receiving 8 mg of nilvadipine for 18 months (Lawlor et al., 2018).”
BackgroundAn optimistic approach to nanotechnology in Alzheimer's disease management: An overview
Tiwari, V., Tiwari, A., Sharma, A., Kumar, M., Kaushik, D. K., & Sagadevan, S. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.104722 · Cited by 15
Repurposing Licensed Drugs for Use Against Alzheimer’s Disease
Norins, L. C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210080 · Cited by 15
Moezzi, S.-M.-I., Mozafari, N., Fazel-Hoseini, S.-M., Nadimi-Parashkoohi, S., Abbasi, H., Ashrafi, H., & Azadi, A. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00637 · Cited by 13
Current and Emerging Therapeutic Approaches for Vascular Cognitive Impairment and Dementia
Goodall, L., Lennon, M. J., Sachdev, P. S., Gorelick, P. B., Kovacic, J. C., & Samaras, K. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.09.1502 · Cited by 17
Mullane, K., & Williams, M. J. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.01.004 · Cited by 14
Herring, A., Kurapati, N. K., Krebs, S., Grammon, N., Scholz, L. M., Voss, G., Miah, M. R., Budny, V., Mairinger, F. D., Haase, K., et al. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12687 · Cited by 18
Metadata
- Authors
- Lawlor, B., Segurado, R., Kennelly, S., Olde Rikkert, M. G. M., Howard, R., Pasquier, F., Börjesson-Hanson, A., Tsolaki, M., Lucca, U., Molloy, D. W., Coen, R., Riepe, M. W., Kálmán, J., Kenny, R. A., Cregg, F., O'Dwyer, S., Walsh, C., Adams, J., Banzi, R., Breuilh, L., Daly, L., Hendrix, S., Aisen, P., Gaynor, S., Sheikhi, A., Taekema, D. G., Verhey, F. R., Nemni, R., Nobili, F., Franceschi, M., Frisoni, G., Zanetti, O., Konsta, A., Anastasios, O., Nenopoulou, S., Tsolaki-Tagaraki, F., Pakaski, M., Dereeper, O., de la Sayette, V., Sénéchal, O., Lavenu, I., Devendeville, A., Calais, G., Crawford, F., Mullan, M., & for the NILVAD Study Group
- Affiliations
- Trinity College Dublin (IE)
- University College Dublin (IE)
- King's College London (GB)
- Université de Lille (FR)
- G. Papanikolaou General Hospital (GR)
- Mario Negri Institute for Pharmacological Research (IT)
- University College Cork (IE)
- St. James's Hospital (IE)
- Universität Ulm (DE)
- University of Szeged (HU)
- University of Limerick (IE)
- University of Southern California (US)
- Rijnstate Hospital (NL)
- Maastricht University (NL)
- University of Milan (IT)
- Ospedale Policlinico San Martino (IT)
- MultiMedica (IT)
- Centro San Giovanni di Dio Fatebenefratelli (IT)
- Aristotle University of Thessaloniki (GR)
- Centre Hospitalier d'Arras (FR)
- Centre Hospitalier de Lens (FR)
- Centre Hospitalier de Béthune (FR)
- Centre Hospitalier Universitaire Amiens-Picardie (FR)
- Groupe Hospitalier de l'Institut Catholique de Lille (FR)
- Roskamp Institute (US)
- Corresponding author
- Lawlor, Brian
- ORCID
- Lawlor, Brian
- Segurado, Ricardo
- Olde Rikkert, Marcel G. M.
- Howard, Robert
- Pasquier, Florence
- Tsolaki, Magda
- Lucca, Ugo
- Molloy, D. William
- Riepe, Matthias W.
- Kálmán, János
- Kenny, Rose Anne
- Walsh, Cathal
- Banzi, Rita
- Daly, Leslie
- Hendrix, Suzanne
- Aisen, Paul
- Sheikhi, Ali
- Verhey, Frans R.
- Nobili, Flavio
- Franceschi, Massimo
- Frisoni, Giovanni
- Zanetti, Orazio
- Konsta, Anastasia
- Nenopoulou, Styliani
- Tsolaki-Tagaraki, Fani
- Lavenu, Isabelle
- Crawford, Fiona
- Mullan, Michael
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-09-24
- Volume
- 15
- Issue
- 9
- Pages
- e1002660
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC6152871
- OpenAlex
- W2891955176
- Cited by
- 193
- References
- 29
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 15 · 2023: 18 · 2022: 18 · 2021: 36 · 2020: 49 · 2019: 24 · 2018: 1
- FWCI
- 18.91
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Arrow@dit (Dublin Institute of Technology) (acceptedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Cork Open Research Archive (University College Cork, Ireland) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by-nc-sa)
- Figshare (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Limerick Institutional Repository (University of Limerick) (submittedVersion, cc-by-nc-sa)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Funders
- National Institute for Health and Care Research (NF-SI-0616-10042)
- European Commission (279093)
- Agence Nationale de la Recherche (ANR-11-LABX-0009)
- University College London Hospitals NHS Foundation Trust
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- nilvadipine, Alzheimer's disease, cognitive decline, dihydropyridine calcium channel blockers, disease-modifying therapy, Clinical Dementia Rating, NINCDS-ADRDA criteria, anti-inflammatory activity, amyloid, regional cerebral blood flow, adverse events
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Calcium Channel Blockers, Double-Blind Method, Europe, Female, Humans, Male, Middle Aged, Nifedipine, Treatment Outcome, Disease Progression, Nootropic Agents, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.